|
||
| |||||||
Oxford, UK – 4 March 2005: Oxford BioMedica (LSE:OXB.L), the leading gene therapy company, today announces that Nick Woolf has been promoted to the Board as an executive director. He will maintain his title of Senior Vice President for Corporate Strategy. His primary responsibilities include corporate finance, M&A evaluation and corporate communications as well as an important role, jointly with Peter Nolan, in business development and deal negotiation. Prior to joining Oxford BioMedica in 2002, Nick spent eight years as a top-rated biotechnology and pharmaceutical analyst. Nick has been involved in all aspects of company financing, ranging from IPOs to major corporate deals. He served as Director and Head of European Biotechnology Research at ABN AMRO, and was previously with Robertson Stephens International, Nomura and SBC Warburg. Nick holds an MA from Oxford University in Chemistry. Commenting on the Board appointment, Professor Alan Kingsman, Chief Executive of Oxford BioMedica, said: “Nick has contributed at a very high level to all corporate activities and has been instrumental in raising the company’s profile in the industry and the investment community. We are delighted to welcome him to the Board.” -Ends-
Notes to editors1. Oxford BioMedica Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange. Oxford BioMedica has core expertise in gene delivery, as well as in-house clinical, regulatory and manufacturing know-how. In oncology, the pipeline includes an immunotherapy and a gene therapy in multiple Phase II trials, and a preclinical targeted antibody therapy in collaboration with Wyeth. In neurotherapy, the Company’s lead product is a gene therapy for Parkinson’s disease, which is expected to enter clinical development in 2005, and four further preclinical candidates. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. The Company has a staff of approximately 65 split between its main facilities in Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California. Oxford BioMedica has corporate collaborations with Wyeth, Intervet, Amersham, Viragen, MolMed and Kiadis; and has licensed technology to a number of companies including Merck & Co and Biogen Idec. Further information is available at www.oxfordbiomedica.co.uk.
|
|
| ||||||||